Profusa (PFSA) Income from Continuing Operations (2022 - 2026)
Profusa's (PFSA) quarterly Income from Continuing Operations came in at -$5.0 million in Q2 2026, up 39.55% on a YoY basis from -$3.6 million in Q2 2025, and down 21.86% quarter-over-quarter from -$4.1 million in Q1 2026.
Powered by 
Analysis
Profusa (PFSA) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Profusa (PFSA) has reported Income from Continuing Operations for 5 consecutive years, with -$5.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations rose 39.55% year-over-year to -$5.0 million; the trailing twelve-month figure through Jun 2026 stood at -$35.8 million (down 112.91% YoY), and the FY2025 full-year result was -$30.3 million, down 247.04% from the prior year.
- Income from Continuing Operations declined to -$5.0 million in Q2 2026 per PFSA's latest filing, from -$4.1 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $3.7 million in Q1 2022 and bottomed at -$23.2 million in Q3 2025.
- Historically, Income from Continuing Operations has averaged -$2.5 million across 5 years, with a median of -$382416.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations surged 124.82% in 2024, then tumbled 25492.37% in 2025.
- Over 5 years, Income from Continuing Operations stood at $482545.0 in 2022, then slumped by 55.92% to $212692.0 in 2023, then slumped by 3672.63% to -$7.6 million in 2024, then surged by 51.99% to -$3.6 million in 2025, then slumped by 35.83% to -$5.0 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered -$5.0 million, -$4.1 million, and -$3.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 184.57 Bn | 178.97 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Intuitive Surgical | 124.13 Bn | 118.91 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Medtronic | 118.29 Bn | 109.47 Bn | 6.34 Bn | 1.48 Bn |
| 4 | Stryker | 104.60 Bn | 101.12 Bn | 4.50 Bn | 1.28 Bn |
| 5 | Boston Scientific | 66.50 Bn | 65.97 Bn | 3.85 Bn | 905.00 Mn |
| 6 | Edwards Lifesciences | 49.72 Bn | 45.46 Bn | 1.35 Bn | 241.40 Mn |
| 7 | Alcon | 33.97 Bn | 32.51 Bn | 1.68 Bn | -92.00 Mn |
| 8 | Dexcom | 32.23 Bn | 30.29 Bn | 830.00 Mn | 249.10 Mn |
| 9 | Steris | 21.16 Bn | 20.68 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Profusa | 141,306.20 | -577,693.80 | - | -4.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.96 Mn |
| Mar 31, 2026 | -4.07 Mn |
| Dec 31, 2025 | -3.65 Mn |
| Sep 30, 2025 | -23.15 Mn |
| Jun 30, 2025 | -8.20 Mn |
| Mar 31, 2025 | -1.12 Mn |
| Dec 31, 2024 | -7.60 Mn |
| Sep 30, 2024 | 91,177.00 |
| Jun 30, 2024 | -397,487.00 |
| Mar 31, 2024 | -820,277.00 |
| Dec 31, 2023 | 212,692.00 |
| Sep 30, 2023 | -367,345.00 |
| Jun 30, 2023 | 852,389.00 |
| Mar 31, 2023 | 440,895.00 |
| Dec 31, 2022 | 482,545.00 |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | 3.71 Mn |